Kornimate/medical-research-clean huggingface dataset:
tailored intervention to improve patient adherence to secondary stroke prevention medication

Conditions: Stroke; Transient Ischemic Attack

Summary: patient suffering a transient ischemic attack (tia) or stroke are subsequently at high risk of a new stroke, however, poor adherence to secondary prevention medications occurs frequently within this patient group. the purpose of this study is to evaluate whether a complex tailored pharmacist intervention will lead to increased adherence to secondary stroke prevention medications and less new stroke events when compared to a usual care group. interventions focus on motivational interviewing, medication review and telephone follow up.


Eligibility criteria:
inclusion criteria: * age: 18 years or older * patient admitted or receiving ambulatory treatment for an acute transient ischemic attack or ischemic stroke which has occurred within the previous 30 days. * the patient or a carer usually dispenses the patient's medications * written consent exclusion criteria: * cognitive or physical impairment that would preclude comprehension of a conversation * terminal illness * lives in a care home or an institution * receives dose dispensed medicine from a pharmacy * medicine is dispensed by a nurse in the patient's home * correctional mental health patients

Keywords: stroke ischemic attack, transient medication adherence motivational interviewing stroke prevention
a study of atezolizumab compared with docetaxel in participants with locally advanced or metastatic non-small cell lung cancer who have failed platinum-containing therapy

Conditions: Non-Squamous Non-Small Cell Lung Cancer

Summary: this global, multicenter, open-label, randomized, controlled study evaluated the efficacy and safety of atezolizumab (an anti-programmed death-ligand 1 \[anti-pd-l1\] antibody)compared with docetaxel in participants with locally advanced or metastatic non-small cell lung cancer (nsclc) after failure with platinum-containing chemotherapy. participants were randomized 1:1 to receive either docetaxel or atezolizumab. treatment may continue as long as participants experienced clinical benefit as assessed by the investigator, i.e., in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression.


Eligibility criteria:
inclusion criteria: * locally advanced or metastatic (stage iiib, stage iv, or recurrent) nsclc * representative formalin-fixed paraffin-embedded (ffpe) tumor specimens * disease progression during or following treatment with a prior platinum-containing regimen for locally advanced, unresectable/inoperable or metastatic nsclc or disease recurrence within 6 months of treatment with a platinum-based adjuvant/neoadjuvant regimen or combined modality (e.g., chemoradiation) regimen with curative intent * measurable disease, as defined by response evaluation criteria in solid tumors (recist) version 1.1 * eastern cooperative oncology group (ecog) performance status of 0 or 1 exclusion criteria: * known active or untreated central nervous system (cns) metastases * malignancies other than nsclc within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome * history of autoimmune disease * history of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening chest computed tomography (ct) scan. history of radiation pneumonitis in the radiation field (fibrosis) is permitted * active hepatitis b or hepatitis c * prior treatment with docetaxel * prior treatment with cluster of differentiation 137 (cd137) agonists, anti-cytotoxic-t-lymphocyte-associated antigen 4 (anti-ctla4), anti-programmed death-1 (anti-pd-1), or anti-pd-l1 therapeutic antibody or pathway-targeting agents
duloxetine for pain in older adults with knee osteoarthritis (oa)

Conditions: Pain Reduction; Function Improvement

Summary: osteoarthritis (oa), a common disabling condition, is the commonest type of arthritis worldwide.pain is the leading symptom and is often chronic in na. current treatment options have had limited symptomatic effect and are associated with significant side effects. duloxetine, a selective serotonin norepinephrine reuptake inhibitor has been demonstrated to have, besides its antidepressant properties, a centrally acting analgesic effect. the aim of the present study was to investigate the efficacy of duloxetine in reducing pain in older adults with knee oa. 288 patients aged 65 years and above with acr clinical and radiographic criteria of primary knee oa attending the outpatient clinic of our institution were enrolled in this study. all patients underwent a physical examination and where questioned about the number of flares. exclusion criteria included any inflammatory, autoimmune, psychiatric illness and morbid obesity. patients were randomized 1:1. one hundred and forty four received 60mg/day of duloxetine hcl and 144 received placebo together with their usual therapy for 16 weeks. the primary outcome measure was pain reduction. secondary outcome measures included improvements in physical functioning scores. pain was assessed using the brief pain inventory (bpi) and visual analogue pain scale, (vas, 0-100 mm). functional assessment using the self-reported physical function as measured with the western ontario and mcmaster universities osteoarthritis index (womac), womac pain and stiffness scores and the geriatric depression scale (gds) was conducted. alterations in dosage of analgesic/nsaid drugs used were recorded. safety and tolerability were also assessed. data was collected at baseline and at monthly intervals for 4 months. all staff involved in data collection was blinded to the treatment assignment groups.


Eligibility criteria:
inclusion criteria: * primary knee osteoarthritis exclusion criteria: * inflammatory conditions * autoimmune disorders * psychiatric illness * morbid obesity

Keywords: duloxetine osteoarthritis pain function
clinical trial of recombinant human papillomavirus virus 16/18 bivalent vaccine

Conditions: Cervical Cancer

Summary: this phase i clinical study was designed to evaluate the safety of novel recombinant hpv 16/18 bivalent vaccine, manufactured by xiamen innovax biotech co., ltd., in healthy women 18-55 years of age at enrolment. approximately 30 study subjects will receive the novel hpv vaccine administered intramuscularly according to a 0-1-6 month schedule.


Eligibility criteria:
inclusion criteria: * written informed consent from the subject prior to enrolment; * female between, and including, 18 and 55 years of age at the time of enrolment; * subjects must be free of obvious health problems; * not pregnant and having no plan for pregnancy; exclusion criteria: * pregnant or breastfeeding or having plan for pregnancy during the whole study (month 0-7); * previous vaccination against hpv; * having severe allergic history or other immunodeficiency; * chemotherapy and other immunosuppressive agents using;

Keywords: human papillomavirus vaccine
ketoconazole, hydrocortisone and dutasteride in asymptomatic hormone refractory prostate cancer

Conditions: Prostate Cancer

Summary: the combination of ketaconazole and hydrocortisone is commonly used for the treatment of prostate cancer. the purpose of this study is to determine if the addition of a drug called dutasteride to this approved combination will make the combination more effective in treating prostate cancer.

* participants will be seen by the study physician every four weeks and have a short physical examination, blood tests and be asked to provide information about their condition. every three months they will undergo a bone scan. if the ct scan that was obtained before the participant started the study shows evidence of cancer, they will be asked to repeat this test every three months. * ketaconazole will be taken orally three times a day on an empty stomach. hydrocortisone will be taken orally in the morning and at night. dutasteride will be taken orally once a day. * participants may remain on study drug until there is evidence of disease progression.

Eligibility criteria:
inclusion criteria: * histologically documented evidence of prostate cancer (needle biopsy or prostatectomy). in the abscence of histologically documented evidence of prostate cancer, the diagnosis must be based on elevated serum psa and metastatic lesions on bone scan. * progressive hrpc defined as a psa increase over baseline of \>25% or 5ng/ml or new lesions on bone/ct scan after conventional androgen deprivation and antiandrogen withdrawal. evidence of metastatic disease based on positive ct or bone scan is not required. * psa of greater than or equal to 2ng/ml and serum total testosterone less than or equal to 50ng/ml * prior chemotherapy is permitted if discontinued \> 4 weeks prior to starting therapy * prior therapy with estrogens is permitted but must have been discontinued \> 4 weeks prior to registration * ecog performance status 0-2 * adequate renal function, hepatic function, and bone marrow function as outlined in protocol * ecg showing a normal qt interval exclusion criteria: * prior therapy with ketoconazole or corticosteroids for hrpc * major surgery or radiation therapy within 4 weeks * strontium-89 or samarium-153 therapy within 4 weeks * thromboembolism in past 6 months * patients who are taking drugs that may further prolong qt intervals and present a known risk for torsades de pointes. * concomitant use of drugs known to be narrow therapeutic index ctp3a4 * drugs that are sensitive cyp3a4 substrates * alcohol or drug dependence currently or in the last 6 months

Keywords: hormone refractory khad ketoconazole dutasteride hydrocortisone
prosaic-ds study (prostate ai in cancer - decision support)

Conditions: Prostate Cancer

Summary: around 375,000 cancers are diagnosed in the uk annually, with this figure expected to reach 500,000 by 2035. as the number of different cancer treatment options and our scientific understanding continue to grow rapidly, it can be difficult for clinicians to keep up-to-date with best practice, causing unjustified variations in the quality of care and clinical outcomes for patients. currently, when a patient has been referred to and seen by a clinician, their treatment is then discussed in a multi-disciplinary team meeting (mdtm). mdtm is a meeting of medical experts, including surgeons, oncologists, nurses, and specialists in cancer, imaging and diagnosis. this is the case even if a treatment decision is straightforward. a nationwide review published by cruk in 2017 highlighted the demands on cancer teams and the mdtm process: * increased caseloads are causing dramatic increases in the time spent by clinicians in mdtms, leading to an unsustainable rise in costs: the cost in england has increased from £88m to £159m in 4 years; * there is not enough time in the mdtm to discuss complex cases; * there is a failure to involve patients in the decision-making process: around 75% of patients feel their views are unrepresented in mdtms; in our study we are looking at the potential of technology - particularly clinical decision support systems (cdss) - to improve mdtm decision making. deontics has a ce marked ai-based cdss that integrates individual patient data and preferences with evidence-based clinical guidelines. this dynamically and transparently generates best-practice, individualised treatment recommendations which can help determine treatment. deontics' ai tool has already been shown to provide personalised recommendations concordant with uk best practice while incorporating patient values, and can be used to safely triage less complex patients straight to treatment with minimal clinical oversight. our project partners with deontics to develop prosaic-ds - a cdss for prostate cancer.

i

Eligibility criteria:
inclusion criteria: * all patients referred to the gstt and kch prostate mdt meetings where sufficient information is available for the mdt to make a treatment decision (approximately 40-50 per week) will be eligible for the study. exclusion criteria: * if data available for patients is not adequate to make any treatment decisions they will be excluded. non-consenting patients will be excluded.
bariatric surgery and pharmacokinetics of candesartan

Conditions: Obesity, Morbid

Summary: changes to gastric ph, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. these factors are potentially influenced by bariatric surgery. little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. in this study the pharmacokinetic effects of bariatric surgery on candesartan are investigated.


Eligibility criteria:
inclusion criteria: * preparing to undergo gastric bypass or sleeve gastrectomy in central norway * being a norwegian citizen exclusion criteria: * having previously undergone resections in the gi-tract

Keywords: bariatric surgery gastrointestinal tract biological availability pharmacokinetics candesartan
evaluation of volume status, haemodynamics and microcirculatory flow in adult patients with severe falciparum malaria

Conditions: Severe Falciparum Malaria

Summary: acidosis, acute renal failure and acute pulmonary oedema are common, and frequently fatal, manifestations of severe p. falciparum malaria. the course of all three might be ameliorated by optimising a patient's intravenous fluid therapy. the fluid treatment of severe malaria is presently empirical, by defining cardiovascular responses to volume replacement we would provide a physiological basis for resuscitation strategies. we will use pulse contour cardiac output monitoring (piccotm) to guide the fluid resuscitation of patients admitted to intensive care with severe malaria. with data collected during the patients' admission we hope to: 1. assess the degree of hypovolaemia in adults with severe malaria and its contribution to microcirculatory dysfunction and acidosis. 2. to assess the relationships between volume status, haemodynamic parameters and the renal and pulmonary manifestations of severe malaria. 3. to assess the utility of central venous pressure measurement as a guide for fluid administration in patients with severe malaria 4. to investigate the prognostic and clinical utility of central venous oxygen saturation in severe malaria in this way we hope to develop a greater understanding of the pathophysiology of haemodynamic derangement in severe malaria. by comparing the picco derived data with simpler clinical parameters, we hope to determine potential fluid resuscitation strategies - relevant for a resource poor setting - whose efficacy could be confirmed in future trials.


Eligibility criteria:
inclusion criteria 1. severe malaria, defined by the modified criteria of hien et al and the presence of asexual forms of p. falciparum in the peripheral blood smear. 2. the patients or their attending relative able and willing to give fully informed written consent. 3. age ≥ 16 years exclusion criteria 1. patients or relatives unable or unwilling to give informed consent.

Keywords: falciparum malaria volume haemodynamics
use of virtual reality to improve sensorimotor function in patients with traumatic wrist and hand injuries

Conditions: Wrist Injury

Summary: the goal of this randomized clinical trial is to compare how the incorporation of virtual reality could influence in proprioception, kinesiophobia, functionality and catastrophism in people that are undergoing a rehabilitation treatment after a wrist fracture. the principal questions it aims to answer are: * evaluate the effect of using virtual reality added to standard rehabilitation of wrist injuries in proprioception impairment. * evaluate the effect of using virtual reality on psychological factors as kinesiophobia and catastrofism. * evaluate the effect of using virtual reality in functionality on wrist-injured patients. intervention will be: * control group: participants of this group will receive conventional rehabilitation of the wrist, plus a specific proprioceptive exercise program. * experimental group: participants of this group will receive the same treatment as the control group but adding virtual reality games at the end of the session. researchers will compare control and experimental group to see if an implantation of virtual reality could had benefits on function, kinesiophobia, catastrofism and proprioception.


Eligibility criteria:
inclusion criteria: * adult (equal or more than 18 y/o). * suffering wrist injury * agree and sign informed consent. exclusion criteria: * not had suffered a wrist injury * suffer from any mental, cognitive, neurological or musculoskeletal disorder * have cervical pathology/impairment * have visual or balance problems

Keywords: wrist injury proprioception virtual reality
advanced care management in patients with advanced heart failure

Conditions: Advanced Heart Failure

Summary: the purpose of this study is to explore the trajectory of advanced management care in patients with heart failure over a period of 9 months, then comparing the medical treatment accepted by patients after 2 years later and compliance with the preferences of patients and their families.

this study is to observe the trajectory of the advanced care management on patients with advanced heart failure and follow the difference between the actual medical treatment accepted by patients on 2years later and the preference of the patient and their families. the advance care management in this study is mean the patients who know about the preference of medical treatment, communication, and prognosis of illness. we also measure the sense of coherence, self-efficacy and their quality of life to compare their relationship of the advanced care management.

Eligibility criteria:
inclusion criteria: * diagnosed with aha stage d, or nyha class function 4, or lvef\<=30%. * has one or more than one symptoms such as dyspnea, lower legs edema, weakness. * ever admission to the hospital (include emergency room or the general room) exclusion criteria: * with other end-stage diseases such cancer, dementia, copd, esrd...etc. * had other physical, cognitive, or psychological condition which may influence their answer.

Keywords: advanced care management, advanced heart failure
clinical trial to assess the efficacy and safety of 'innocell immuncell-lc' with temozolomide in newly diagnosed glioblastoma of korea

Conditions: Glioblastoma

Summary: this clinical study was planned in order to assess the superiority of innocell corp. "immuncell-lc" in aspects of therapeutic efficacy and safety when administered with temozolomide to glioblastoma patients when compared with the control group who did not receive administration of the drug.

\ compare clinical efficacy of group treated with cell theraputic innocell immuncell-lc evaluated by progression free survival with that of untreated group. \ compare clinical efficacy of group treated with innocell immuncell-lc, a drug for treating glioblastoma evaluated by overall survival, therapy reaction, eortc qlq-c30, and karnofsky performance status (kps) and that of untreated group, and evaluate adverse reactions, clinical pathological tests, and its safety.

Eligibility criteria:
inclusion criteria: 1. patients who, prior to the study, received explanation of the purpose and content of study and of characteristics of the test drug from the test administrator and have consented to the study by providing signature of self, guardian, or legal representative. 2. patients who are between 18 and 70 years of age 3. patients whose cause of cancer has been found to be glioblastoma via pathological testing 4. patients who have received surgery for glioblastoma (complete or partial extirpation or biopsy) 2 weeks prior to the study 5. patients whose survival is expected to be longer than 3 months 6. patients whose kps is greater than 60 7. patients who satisfy the following conditions of the blood test, kidney function test, and liver function test * hemoglobin is bigger than 10 gm% * platelet count is bigger than 100,000/µl * absolute granulocyte count is bigger than 1,500/µl * bun or creatinine 1.5 x upper normal limit * bilirubin level is smaller than 2.0 mg/dl * sgot, sgpt, alkaline phosphatase is smaller than 1.5 x upper normal limit exclusion criteria: 1. patients who have been determined to have serious cardio - pulmonary function disability by the clinical study staff 2. patients who are immune deficient or have a history of auto immune diseases (ex. rheumatoid arthritis, systemic lupus erythematosus, vasculitis, multiple sclerosis, adolescent insulin-dependent diabetes mellitus, etc.) 3. patients who have a history of malignant tumors in the recent 5 years prior to the study with the exception of skin cancer, local prostate cancer, and cervical cancer. 4. patients with history of severe allergies 5. patients with serious mental illness 6. patients who are pregnant or nursing 7. patients who have participated in other clinical tests in the recent 4 weeks prior to the study

Keywords: glioblastoma newly diagnosed glioblastoma
future innovations in novel detection of heart failure find-hf

Conditions: Heart Failure

Summary: heart failure (hf) is increasingly common and associated with excess morbidity, mortality and healthcare costs. new medications are now available which can alter the disease trajectory and reduce clinical events. however, many cases of hf remain undetected until presentation with more advanced symptoms, often requiring hospitalisation. earlier identification and treatment of hf could reduce downstream healthcare impact, but predicting hf incidence is challenging due to the complexity and varying course of hf. the investigators will use routinely collected hospital-linked primary care data and focus on the use of artificial intelligence methods to develop and validate a prediction model for incident hf. using clinical factors readily accessible in primary care, the investigators will provide a method for the identification of individuals in the community who are at risk of hf, as well as when incident hf will occur in those at risk, thus accelerating research assessing technologies for the improvement of risk prediction, and the targeting of high-risk individuals for preventive measures and screening.


Eligibility criteria:
inclusion criteria: 1. aged 16 years and older 2. no history of heart failure 3. a minimum of one year follow up exclusion criteria: -

Keywords: heart failure prediction model
hypotonic treprostinil subcutaneous infusion for control of treprostinil related site pain

Conditions: Pulmonary Arterial Hypertension

Summary: the investigators will test whether hypotonic (diluted) remodulin solution causes less pain than the eutonic (undiluted) solution supplied by the manufacturer.


Eligibility criteria:
inclusion criteria: * pah by standard criteria * treatment with subcutaneous remodulin infusion for at least 3 months, with stable dose for 1 month * pain at infusion site (defined as \> 8 on mcgill pain questionnaire) exclusion criteria: * known pregnancy or breastfeeding

Keywords: subcutaneous treprostinil